Iotroxic acid

From WikiProjectMed
(Redirected from Meglumine iotroxate)
Jump to navigation Jump to search
Iotroxic acid
Names
Trade namesBiliscopin, others
  • 3-{2-[2-(2-{[(3-carboxy-2,4,6-triiodophenyl)carbamoyl]methoxy}ethoxy)ethoxy]acetamido}-2,4,6-triiodobenzoic acid
Clinical data
Defined daily dosenot established[1]
External links
AHFS/Drugs.comInternational Drug Names
Chemical and physical data
FormulaC22H18I6N2O9
Molar mass1215.818 g·mol−1
3D model (JSmol)
  • O=C(Nc1c(I)c(c(I)cc1I)C(=O)O)COCCOCCOCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I


Iotroxic acid, also known as meglumine iotroxate, is a molecule used as a contrast medium during X-rays.[2][3] It is specifically used during tests looking at the gallbladder and biliary tract.[3] It is given by slow injection into a vein.[3]

Side effects are uncommon.[4] They include vomiting, skin flushing, headache, itchiness, and low blood pressure.[3] Rare side effects include seizures and allergic reactions.[3] It should not be used by those who have an iodine allergy.[3] Iotroxic acid is an iodine containing contrast media of the diionic dimer type.[5]

Iotroxic acid was first made in 1976.[6] It is on the World Health Organization's List of Essential Medicines.[7] It is rarely used in the developed world due to the availability of magnetic resonance cholangiopancreatography (MRCP).[8]

Dosage

The defined daily dose is not established.[1]

References

  1. ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 21 November 2020. Retrieved 15 September 2020.
  2. ↑ "Iotroxic Acid - Drugs.com". www.drugs.com. Archived from the original on 31 December 2016. Retrieved 31 December 2016.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 315, 318. hdl:10665/44053. ISBN 9789241547659.
  4. ↑ Neugebauer, Edmund; Sauerland, Stefan (2014). Recommendations for evidence-based endoscopic surgery: The updated EAES consensus development conferences. Springer Science & Business Media. p. 67. ISBN 9782817808499. Archived from the original on 2017-01-01.
  5. ↑ Schaefer, Christof; Peters, Paul W. J.; Miller, Richard K. (2014). Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. Academic Press. p. 532. ISBN 9780124079014. Archived from the original on 2017-01-01.
  6. ↑ Korolkovas, Andrejus (1988). Essentials of Medicinal Chemistry. Wiley. p. 1063. ISBN 9780471883562. Archived from the original on 2017-01-01.
  7. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ↑ Sherlock, Shiela; Dooley, James (2008). Diseases of the Liver and Biliary System. John Wiley & Sons. p. 568. ISBN 9780470986813. Archived from the original on 2017-01-01.

External links

Identifiers:
  • "Iotroxic Acid". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-11-16. Retrieved 2020-05-17.
Stub icon

This pharmacology-related article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Iotroxic_acid&oldid=1439758"